<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247584</url>
  </required_header>
  <id_info>
    <org_study_id>AAML11B2</org_study_id>
    <secondary_id>COG-AAML11B2</secondary_id>
    <secondary_id>NCI-2011-02846</secondary_id>
    <secondary_id>AAML11B2</secondary_id>
    <nct_id>NCT01247584</nct_id>
  </id_info>
  <brief_title>Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Telomere Length and Telomerase Mutations in Pediatric Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying bone marrow samples from patients with cancer in the laboratory may help&#xD;
      doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is studying biomarkers in samples from young patients with acute&#xD;
      myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To compare the frequency of germline telomerase mutations in pediatric patients with&#xD;
           acute myeloid leukemia (AML) demonstrating prolonged myelosuppression, defined as ≥ 1&#xD;
           episode &gt; 35 days of neutrophil count recovery after chemotherapy, to the pediatric&#xD;
           patients with the expected myelosuppression, defined as consistently &lt; 35 days of&#xD;
           neutrophil count recovery after chemotherapy.&#xD;
&#xD;
        -  To assess association between telomerase mutations and incidence of grade 3 or 4&#xD;
           mucositis, relapse, and death.&#xD;
&#xD;
        -  To compare germline (remission) telomere length in pediatric AML patients demonstrating&#xD;
           delayed bone marrow recovery with the pediatric patients with consistently expected&#xD;
           recovery.&#xD;
&#xD;
        -  To assess whether a correlation between telomere length and incidence of grade 3 or 4&#xD;
           mucositis, relapse, and death exist.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Cryopreserved bone marrow samples are analyzed for DNA sequencing and mutation by&#xD;
      Sanger-based sequencing methods, quantitative PCR, and SeqMan Pro (Lasergene from DNAStar).&#xD;
      Results are then compared with previously published data and existing databases to determine&#xD;
      the allele frequency in control populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of mutations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in telomere length</measure>
  </primary_outcome>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of acute myeloid leukemia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia&#xD;
&#xD;
          -  Enrolled on CCG-2961 and meeting 1 of the following criteria:&#xD;
&#xD;
               -  More than 35 days to recover to an ANC &gt; 500/mm³ after any course of chemotherapy&#xD;
&#xD;
               -  Consistently recovered &lt; 35 days to an ANC &gt; 500/mm³ after all courses of&#xD;
                  chemotherapy&#xD;
&#xD;
          -  Available cryopreserved cell from diagnostic and end-of-therapy samples&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria M. Gramatges, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute myeloid leukemia/other myeloid malignancies</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

